KR20250099259A - 과민성 방광의 치료를 위한 비베그론의 용도 - Google Patents

과민성 방광의 치료를 위한 비베그론의 용도 Download PDF

Info

Publication number
KR20250099259A
KR20250099259A KR1020257020007A KR20257020007A KR20250099259A KR 20250099259 A KR20250099259 A KR 20250099259A KR 1020257020007 A KR1020257020007 A KR 1020257020007A KR 20257020007 A KR20257020007 A KR 20257020007A KR 20250099259 A KR20250099259 A KR 20250099259A
Authority
KR
South Korea
Prior art keywords
vibegron
pharmaceutical composition
subject
composition according
over
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257020007A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 씨. 피씨텔리
폴 머드
Original Assignee
유로반트 사이언시즈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62815097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20250099259(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유로반트 사이언시즈 게엠베하 filed Critical 유로반트 사이언시즈 게엠베하
Publication of KR20250099259A publication Critical patent/KR20250099259A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020257020007A 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도 Pending KR20250099259A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762515996P 2017-06-06 2017-06-06
US62/515,996 2017-06-06
US201862635146P 2018-02-26 2018-02-26
US62/635,146 2018-02-26
US201862637961P 2018-03-02 2018-03-02
US62/637,961 2018-03-02
KR1020197038625A KR20200012949A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도
PCT/IB2018/054069 WO2018224989A1 (en) 2017-06-06 2018-06-06 Use of vibegron to treat overactive bladder

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038625A Division KR20200012949A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도

Publications (1)

Publication Number Publication Date
KR20250099259A true KR20250099259A (ko) 2025-07-01

Family

ID=62815097

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257020007A Pending KR20250099259A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도
KR1020197038625A Ceased KR20200012949A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197038625A Ceased KR20200012949A (ko) 2017-06-06 2018-06-06 과민성 방광의 치료를 위한 비베그론의 용도

Country Status (14)

Country Link
US (2) US12102638B2 (enExample)
EP (2) EP4410295A3 (enExample)
JP (3) JP7682605B2 (enExample)
KR (2) KR20250099259A (enExample)
CN (3) CN117695287A (enExample)
AU (2) AU2018282104B2 (enExample)
BR (1) BR112019025636A2 (enExample)
CA (1) CA3064989A1 (enExample)
CL (1) CL2019003533A1 (enExample)
IL (2) IL317220A (enExample)
MX (1) MX2022015629A (enExample)
PH (1) PH12019502651A1 (enExample)
WO (1) WO2018224989A1 (enExample)
ZA (1) ZA202000028B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291632B2 (ja) * 2017-12-21 2023-06-15 杏林製薬株式会社 夜間頻尿治療剤
TW202038963A (zh) * 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆（ｖｉｂｅｇｒｏｎ）於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
TW202506129A (zh) * 2019-03-18 2025-02-16 瑞士商優洛凡特科學公司 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途
DE102020124101A1 (de) 2020-02-04 2021-08-05 Samsung Electronics Co., Ltd. Elektronische vorrichtung mit einer speichervorrichtung und trainingsverfahren
AR124479A1 (es) 2020-12-22 2023-03-29 Urovant Sciences Gmbh Métodos de monitoreo de la digoxina con el uso de vibegrón para el tratamiento de la vejiga hiperactiva
WO2025262600A1 (en) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Crystalline form of vibegron hemihydrate

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100506568B1 (ko) 1997-10-17 2006-04-21 아스텔라스세이야쿠 가부시키가이샤 아미드유도체및이의염,및이를포함하는약제학적제제
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
CA2503570C (en) 2002-11-07 2011-04-19 Yamanouchi Pharmaceutical Co., Ltd. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
CA2524023C (en) 2003-05-05 2011-11-22 Kissei Pharmaceutical Co., Ltd. Use of phenoxyacetic acid derivatives for treating hyperactive bladder
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2008128968A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
KR101586503B1 (ko) 2007-09-13 2016-01-18 코덱시스, 인코포레이티드 아세토페논의 환원을 위한 케토리덕타제 폴리펩티드
SI2216021T1 (sl) 2007-11-02 2013-01-31 Astellas Pharma Inc. Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
SI2329014T1 (sl) 2008-08-29 2015-01-30 Codexis, Inc. Polipeptidi ketoreduktaze za stereoselektivno produkcijo (4s)-3(5s)-5(4-fluorofenil)-5-hidroksipentanoil)-4-fenil-1,3-oksazolidin -2-ona
US20120202819A1 (en) 2009-10-07 2012-08-09 Merck Sharp & Dohme Corporation Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
PE20131341A1 (es) 2010-08-03 2013-12-07 Altherx Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9168254B2 (en) 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
CN106479990B (zh) 2011-11-18 2020-09-18 科德克希思公司 用于制备羟基取代的氨基甲酸酯的生物催化剂
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． β−３作動薬および中間体の製造方法
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
WO2017210700A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
WO2017210696A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
CN110869053A (zh) 2017-06-06 2020-03-06 乌洛万特科学有限公司 给药维贝隆以治疗膀胱过度活动症
JP7291632B2 (ja) 2017-12-21 2023-06-15 杏林製薬株式会社 夜間頻尿治療剤
SG11202010683PA (en) 2018-05-23 2020-12-30 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
TW202038963A (zh) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆（ｖｉｂｅｇｒｏｎ）於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
TW202506129A (zh) 2019-03-18 2025-02-16 瑞士商優洛凡特科學公司 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途
AR124479A1 (es) 2020-12-22 2023-03-29 Urovant Sciences Gmbh Métodos de monitoreo de la digoxina con el uso de vibegrón para el tratamiento de la vejiga hiperactiva
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法

Also Published As

Publication number Publication date
JP2023071826A (ja) 2023-05-23
JP7682605B2 (ja) 2025-05-26
CN117695286A (zh) 2024-03-15
CL2019003533A1 (es) 2020-06-26
EP3634420A1 (en) 2020-04-15
AU2018282104A1 (en) 2019-12-12
US12102638B2 (en) 2024-10-01
KR20200012949A (ko) 2020-02-05
EP4410295A3 (en) 2024-10-16
US20210077495A1 (en) 2021-03-18
CN110869022A (zh) 2020-03-06
AU2018282104B2 (en) 2024-07-11
IL271164A (en) 2020-01-30
ZA202000028B (en) 2025-09-25
CA3064989A1 (en) 2018-12-13
BR112019025636A2 (pt) 2020-08-25
IL317220A (en) 2025-01-01
US20260014158A1 (en) 2026-01-15
MX2022015629A (es) 2023-01-11
WO2018224989A1 (en) 2018-12-13
AU2024204591A1 (en) 2024-07-18
EP4410295A2 (en) 2024-08-07
JP2025063196A (ja) 2025-04-15
PH12019502651A1 (en) 2020-06-08
CN117695287A (zh) 2024-03-15
JP2020522560A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
US20260014158A1 (en) Use of vibegron to treat overactive bladder
US20230218624A1 (en) Dosing of vibegron for treatment of overactive bladder
AU2025271046A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2025032143A (ja) 良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用
TW202015692A (zh) 維貝格龍（ｖｉｂｅｇｒｏｎ）於治療與腸躁症候群相關之疼痛之用途
HK40114255A (en) Use of vibegron to treat overactive bladder
EA045454B1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
EA052961B1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)